Therapeutic Class: Beta-3 Adrenergic Agonist
Indication: Management of overactive bladder (OAB) symptoms such as urgency, frequency, and urge incontinence.
- Do not discontinue without consulting your doctor, even if symptoms don’t improve right away.
- Regular monitoring of blood pressure is recommended during therapy.
- Mirabegron must not be used in individuals with a known allergy to the active ingredient or any of its components. It is also strictly contraindicated in cases of severe, uncontrolled high blood pressure — defined as a systolic pressure ≥180 mm Hg or diastolic pressure ≥110 mm Hg.
- Inform your doctor about any other medications or health conditions before starting Uroben XR 50.
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Uroben XR 50 is used to relieve symptoms of an overactive bladder, including frequent urination, sudden urges to urinate, and inability to control urination. It works by relaxing the bladder muscle and improving its ability to store urine, which reduces the urgency and frequency of urination.
Overactive bladder, with symptoms of urge urinary incontinence, urgency, and urinary frequency
Mirabegron, the active ingredient in Uroben XR 50, is a beta-3 adrenergic receptor agonist. It stimulates receptors in the bladder wall, promoting muscle relaxation and increasing bladder capacity, thereby improving urinary control.
Adults: Start with 25 mg once daily; may increase to 50 mg once daily depending on response and tolerance.
Administration: Can be taken with or without food. Swallow whole — do not chew, crush, or divide.
Renal Impairment:
Severe (CrCl 15–29 mL/min): Do not exceed 25 mg/day.
ESRD: Use not recommended.
Hepatic Impairment:
Moderate (Child-Pugh B): Max 25 mg/day.
Severe (Child-Pugh C): Not recommended
Very common (>10%): Increased blood pressure (especially in patients with existing hypertension)
Common (1–10%):
CYP3A4/P-gp Inhibitors (e.g., ketoconazole, ritonavir, clarithromycin): May increase mirabegron exposure.
CYP3A4/P-gp Inducers (e.g., rifampin): May reduce drug levels.
P-gp substrates (e.g., digoxin): Monitor levels.
Caution with QT-prolonging medications like thioridazine, TCAs, and class 1C antiarrhythmics.
Use with caution in:
Store in a cool and dry place, away from light and moisture. Keep out of reach of children.
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.